Table 3.
Overall survival and time-to-treatment failure after treatment with eribulin
| Soft tissue sarcoma subtypea | n | OS median, months (95% CI) |
TTF median, months (95% CI) |
|---|---|---|---|
| All | 252 | 10.8 (8.5–13.1) | 2.5 (2.1–2.8) |
| L-type | 142 | 13.8 (10.1–22.3) | 2.8 (2.3–3.7) |
| Non-L-type | 110 | 6.5 (5.7–11.1) | 2.2 (1.6–2.6) |
| Leiomyosarcoma | 73 | 12.7 (8.5–20.6) | 2.8 (2.1–3.7) |
| Liposarcoma | 69 | 20.8 (8.9–not reached) | 3.2 (1.7–5.5) |
| Dedifferentiated | 40 | 16.6 (8.8–not reached) | 3.1 (1.7–5.7) |
| Myxoid | 12 | 27.6 (4.1–27.6) | 5.0 (1.0–12.0) |
| Well-differentiated | 7 | not reached (5.8–not reached) | 9.9 (0.5–not reached) |
| Pleomorphic | 3 | 7.3 (6.9–8.5) | 1.4 (1.4–2.0) |
| Unknown | 7 | 5.8 (1.8–not reached) | 1.5 (0.5–5.8) |
| Undifferentiated pleomorphic sarcoma | 19 | 8.1 (4.0–16.3) | 2.3 (1.4–4.0) |
| Angiosarcoma | 14 | 12.7 (3.4–16.9) | 2.4 (0.7–5.5) |
| Synovial sarcoma | 13 | 11.7 (4.5–16.0) | 3.7 (2.3–4.6) |
| Rhabdomyosarcoma | 12 | 4.5 (0.8–9.7) | 1.2 (0.5–2.8) |
| Malignant peripheral nerve sheath tumor | 6 | 3.3 (2.0–5.1) | 1.5 (0.5–2.3) |
| Myxofibrosarcoma | 5 | 11.1 (2.3–19.8) | 8.1 (0.7–8.4) |
CI confidence interval, OS overall survival, TTF time-to-treatment failure
aLimited to subtypes with 5 or more patients